Clinical trial
Imatinib in Adult Patients With Metastatic Ocular Melanoma
NCT00421317 · Centre Oscar Lambret, Other · Terminated
Key facts
| NCT number | NCT00421317 |
|---|---|
| Title | Imatinib in Adult Patients With Metastatic Ocular Melanoma |
| Official title | A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma |
| Acronym | O-Mel-Inib |
| Lead sponsor | Centre Oscar Lambret, Other |
| Collaborators | Novartis Industry National Cancer Institute, France |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 13 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Jan 6, 2016 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: